mProX™ Human ESRRA Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Nuclear Receptor
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human ESRRA Stable Cell Line (S01YF-1123-KX97). Click the button above to contact us or submit your feedback about this product.
Charles (Verified Customer)
Sherry Smith (Creative Biolabs Scientific Support)
Emily (Verified Customer)
Sherry Smith (Creative Biolabs Scientific Support)
Published Data
Fig.1 Genomic amplification and expression of ESRRA in OSCC cell lines.
Four copies of ESRRA were present in the SCC084 and SCC131 cell lines, respectively. In both cell lines, the amount of ESRRA protein was higher than in the normal oral tissue from patient #63.
Ref: Tiwari, Ankana, et al. "Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivo." Scientific Reports 5.1 (2015): 17621.
Pubmed: 26639757
DOI: 10.1038/srep17621
Research Highlights
Estrogen-related receptor α, also known as the orphan nuclear receptor, is a crucial modulator of mitochondrial activity and energy homeostasis. An essential innate effector against intracellular microorganisms is macroautophagy/autophagy, an intracellular breakdown process.
Kim, Soo Yeon, et al. "ESRRA (estrogen-related receptor α) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense." Autophagy 14.1 (2018): 152-168.
Pubmed:
28841353
DOI:
10.1080/15548627.2017.1339001
According to immunohistochemistry and transcriptome profiling, TN-ILC is a distinct aggressive breast cancer that is linked to advanced age and belongs to the luminal androgen receptor subtype. Additionally, it carries certain molecular changes (PI3K, ERBB2, and ESRRA) that could lead to the development of novel targeted treatment approaches.
Bergeron, Anthony, et al. "Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations." Modern Pathology 34.7 (2021): 1282-1296.
Pubmed:
33753865
DOI:
10.1038/s41379-021-00742-9